{"id":308,"date":"2020-06-24T09:03:39","date_gmt":"2020-06-24T09:03:39","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=308"},"modified":"2020-06-24T09:03:39","modified_gmt":"2020-06-24T09:03:39","slug":"23-june-2020-tocilizumab-associated-with-lower-mortality-when-intubated-patients-were-excluded","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/23-june-2020-tocilizumab-associated-with-lower-mortality-when-intubated-patients-were-excluded\/","title":{"rendered":"(23 June 2020) Tocilizumab-   associated with lower mortality, when intubated patients were excluded"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"wi-article-title article-title-main\">Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab \u2013 A Case- Controlled Study<\/p>\n<p>https:\/\/doi.org\/10.1093\/qjmed\/hcaa206<\/p>\n<div class=\"\">\n<p class=\"chapter-para\">We conducted a&nbsp; in patients with&nbsp; disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The primary endpoint was the overall mortality. Secondary endpoints were mortality in non-intubated patients, and mortality in intubated patients.<\/p>\n<\/div>\n<div class=\"\">\n<div class=\"title\">RESULTS<\/div>\n<p class=\"chapter-para\">A total of 193 severe to critical COVID-19 patients were included in this retrospective, case-control, single-center study. 96 patients received tocilizumab, while 97 served as control group. The mean age was 60 years.&nbsp; More patients in the tocilizumab group reported fever, cough, and shortness of breath (83%, 80%, and 96% versus 73%, 69%, and 71%, respectively). There was a non-statistically significant lower mortality in the treatment group (52% versus 62.1% P\u2009=\u20090.09). When excluding intubated patients, there was statistically significant lower mortality in patients treated with tocilizumab (6 vs. 27% P\u2009=\u20090.024). Bacteremia was more common in the control group (24% vs 13% P\u2009=\u20090.43), while fungemia was the similar for both (3% vs 4% P\u2009=\u20090.72). Study showed a non-statistically significant lower mortality in patients with severe to critical COVID-19 disease who received tocilizumab. When intubated patients were excluded, the use of tocilizumab was associated with lower mortality.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab \u2013 A Case- Controlled Study https:\/\/doi.org\/10.1093\/qjmed\/hcaa206 We conducted a&nbsp; in patients with&nbsp; disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The primary&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/23-june-2020-tocilizumab-associated-with-lower-mortality-when-intubated-patients-were-excluded\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(23 June 2020) Tocilizumab-   associated with lower mortality, when intubated patients were excluded&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/308"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=308"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/308\/revisions"}],"predecessor-version":[{"id":309,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/308\/revisions\/309"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}